ISSN:
1432-1041
Keywords:
Parkinsonism
;
DOPA Decarboxylase inhibitor
;
Benserazide
;
L-DOPA
;
Pharmacokinetics
;
Tissue distribution
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary 14C-labelled benserazide was administered to six patients with parkinsonism and total radioactivity was measured in the plasma, urine and faeces. Three patients received benserazide both orally and intravenously, while three other patients received benserazide orally alone and together with L-DOPA (= MADOPAR®). Plasma levels did not follow first-order kinetics, but indicated rapid absorption of an oral dose. Following intravenous and oral administration, excretion of radioactivity was 88.7 and 57.7% respectively in the urine, 10.1 and 30.7% respectively in the faeces. L-DOPA slightly increased the absorption of benserazide. Following the administration of an oral dose to rats benserazide related radioactivity was distributed almost entirely outside the brain. The drug therefore appears to be suitable for blocking extracerebral decarboxylase whilst leaving the intra-cerebral enzyme almost unaffected.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00614388
Permalink
